Schedule 13D ownership disclosure
MARKER THERAPEUTICS INC
Common Stock, par value $0.001 per share · CUSIP: 57055L206
Event date: 2025-08-14
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- New Enterprise Associates 16, L.P.Reported CIK 0001694560
Shares: 1,625,678.00 · Class: 12.6%
- NEA Partners 16, L.P.Reported CIK 0001712881
Shares: 1,625,678.00 · Class: 12.6%
- NEA 16 GP, LLCReported CIK 0001712882
Shares: 1,625,678.00 · Class: 12.6%
- Forest BaskettReported CIK 0001277631
Shares: 1,625,678.00 · Class: 12.6%
- Ali BehbahaniReported CIK 0001613867
Shares: 1,625,678.00 · Class: 12.6%
- Carmen ChangReported CIK 0001746342
Shares: 1,625,678.00 · Class: 12.6%
- Anthony A. Florence, Jr.Reported CIK 0001559827
Shares: 1,625,678.00 · Class: 12.6%
- Mohamad H. MakhzoumiReported CIK 0001630226
Shares: 1,625,678.00 · Class: 12.6%
- Scott D. SandellReported CIK 0001237289
Shares: 1,625,678.00 · Class: 12.6%
- Paul WalkerReported CIK 0001553150
Shares: 1,625,678.00 · Class: 12.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001072613-25-000647
- Form type
- SCHEDULE 13D/A
- Filer
- Marker Therapeutics, Inc.
- CIK
- CIK 1094038
- Filed
- Aug 18, 2025
- Reporting period
- Aug 14, 2025
- Description
- Schedule 13D beneficial ownership